Evotec (NASDAQ:EVO) Shares Gap Down – Here’s Why

Shares of Evotec SE (NASDAQ:EVO) gapped down prior to trading on Thursday . The stock had previously closed at $3.41, but opened at $3.29. Evotec shares last traded at $3.29, with a volume of 4,840 shares changing hands.

Evotec Price Performance

The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. The stock’s fifty day moving average is $4.10 and its 200-day moving average is $4.10.

Institutional Trading of Evotec

Large investors have recently made changes to their positions in the stock. CSS LLC IL acquired a new stake in Evotec in the 4th quarter worth approximately $50,000. Lighthouse Investment Partners LLC acquired a new stake in shares of Evotec in the fourth quarter worth $166,000. Bank of America Corp DE boosted its holdings in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares during the period. BNP Paribas Financial Markets acquired a new position in Evotec in the 4th quarter valued at $27,000. Finally, DCF Advisers LLC grew its stake in Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company’s stock valued at $956,000 after buying an additional 12,816 shares during the last quarter. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.